Last reviewed · How we verify
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
At a glance
| Generic name | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
Common side effects
- Phosphorus intoxication
- Hypocalcemic tetany
- Reduction of serum calcium
Serious adverse events
- Phosphorus intoxication
- Hypocalcemic tetany
Key clinical trials
- Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (PHASE2)
- Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients (PHASE3)
- MORDOR II Burkina Faso: Longitudinal Trial (PHASE4)
- Gut and Azithromycin Mechanisms in Infants and Children II (PHASE4)
- Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids (PHASE1)
- Study of the Efficacy and Safety of Quiklean® and Klean-Prep With Dulcolax® for the Bowel Preparation Prior to Colonoscopy (PHASE3)
- Study of the Safety of USB005 in Healthy Volunteers (PHASE1)
- Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SODIUM PHOSPHATE, DIBASIC, ANHYDROUS CI brief — competitive landscape report
- SODIUM PHOSPHATE, DIBASIC, ANHYDROUS updates RSS · CI watch RSS